secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001437749-25-008014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025
------------------------------------------------------------------------

- Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.
- Cash $44.1M at Dec 31, 2024; runway into Q3 2026; operating cash burn $22.1M.
- Preeclampsia Phase 2 topline safety/efficacy data expected Q2 2025; dosing ongoing.
- ReMEDy2 AIS trial: DSMB cleared new IV dosing; interim analysis of first 200 patients expected H1 2026.
- Appointed Daniel J. O'Connor (former Ambrx CEO) to board in February 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/0001437749-25-008014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/dmtp20250316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-008014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer